olmesartan has been researched along with spironolactone in 8 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (spironolactone) | Trials (spironolactone) | Recent Studies (post-2010) (spironolactone) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 7,222 | 960 | 1,923 |
| Protein | Taxonomy | olmesartan (IC50) | spironolactone (IC50) |
|---|---|---|---|
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Estrogen receptor | Homo sapiens (human) | 5.702 | |
| Glucocorticoid receptor | Homo sapiens (human) | 4.0745 | |
| Progesterone receptor | Homo sapiens (human) | 1.675 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0315 | |
| Androgen receptor | Homo sapiens (human) | 0.3585 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.406 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 6.92 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ando, K; Fujita, M; Fujita, T; Kawarasaki, C; Kawarazaki, H; Matsui, H; Muraoka, K; Nagae, A | 1 |
| Deguchi, K; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Minamino, T; Mori, H; Nakano, D; Nishiyama, A | 1 |
| Hamada, J; Kobara, M; Nakata, T; Noda, K; Shiraishi, T; Tanaka, T; Toba, H; Wang, J; Yoshifuji, Y | 1 |
| Araki, N; Ishigami, T; Kakizoe, Y; Kitamura, K; Maeda, E; Minegishi, S; Tamura, K; Umemura, M; Umemura, S; Ushio-Yamana, H | 1 |
| O'Brien, E | 1 |
| di Mario, C; Francis, DP; Hayward, C; Krum, H; Lyon, AR; Ozdemir, BA; Patel, HC; Rosen, SD | 1 |
1 review(s) available for olmesartan and spironolactone
| Article | Year |
|---|---|
Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation.
Topics: Amides; Antihypertensive Agents; Benzimidazoles; Benzopyrans; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Control Groups; Double-Blind Method; Drug Resistance; Eplerenone; Ethanolamines; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Nebivolol; Oxadiazoles; Placebo Effect; Placebos; Randomized Controlled Trials as Topic; Regression Analysis; Research Design; Spironolactone; Sympathectomy; Tetrazoles; Treatment Outcome | 2015 |
7 other study(ies) available for olmesartan and spironolactone
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats.
Topics: Acute Kidney Injury; Aldosterone; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Eplerenone; Hypertension; Imidazoles; Immunohistochemistry; Kidney; Male; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; Sodium Chloride; Spironolactone; Tetrazoles | 2011 |
Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.
Topics: Actins; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cellular Senescence; Eplerenone; Genes, p16; Genes, p53; Hydralazine; Hypertension; Imidazoles; Kidney; Mice; Mice, Inbred C57BL; p21-Activated Kinases; Sirtuin 1; Sodium Chloride; Spironolactone; Tetrazoles | 2012 |
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Drug Therapy, Combination; Heart Failure; Hemodynamics; Imidazoles; Lipid Peroxidation; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; NADPH Oxidases; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Ventricular Function, Left | 2012 |
Renin angiotensin antagonists normalize aberrant activation of epithelial sodium channels in sodium-sensitive hypertension.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Down-Regulation; Epithelial Sodium Channels; Eplerenone; Hypertension; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Perindopril; Renin; Sodium; Sodium Chloride, Dietary; Spironolactone; Tetrazoles | 2012 |
If I had resistant hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Pyrroles; Spironolactone; Tetrazoles; Treatment Failure; Treatment Outcome | 2014 |